Arbutus Biopharma Corporation filed the tender offer documents Thursday morning, setting a price range with a $5.00 floor for up to $230 million in common shares. The modified Dutch auction allows shareholders to tender at their chosen price within a specified band, with the company paying the lowest price that lets it buy the full amount. At $5.00, the floor sits 22% below the stock's recent trading range, an unusual spread for a clinical-stage name with two hepatitis B programs in mid-stage trials.

The company holds roughly $400 million in cash and marketable securities as of its last quarterly filing, meaning this tender consumes more than half the balance sheet before a pivotal data readout. Arbutus is twelve months from reporting Phase 2b results for imdusiran, a subcutaneous RNAi therapeutic targeting hepatitis B surface antigen. The tender closes before that catalyst, suggesting management sees the current valuation as materially disconnected from the asset's risk-adjusted probability. Clinical-stage biotechs rarely return capital at this scale unless they expect either a partnership with upfront payment or a significant revaluation event that makes current shares cheap.

The infectious disease focus is narrow but durable. Arbutus owns oral capsid inhibitor AB-836 in Phase 2a and the RNAi candidate in Phase 2b, both targeting functional cure in chronic hepatitis B. The market for functional cure therapies is estimated at $8 billion annually, with Gilead Sciences and GSK holding early leads but no approved product. A clean Phase 2b dataset would shift partnership economics sharply in Arbutus's favor, and management knows it. The tender offer at a 22% discount is a declared view: either institutions are wrong, or the company plans to shrink the float ahead of a term sheet.

Operators should track three items. First, the actual clearing price when the tender closes, likely within 30 days. If it clears near $5.00, management called the bottom. If it clears higher, demand is tighter than the filing suggests. Second, any partnership announcements within 90 days of the tender close. A capital return followed by a deal would confirm the playbook. Third, the imdusiran Phase 2b interim analysis, expected in Q3 2027. If the company accelerates that timeline, the tender becomes a liquidity positioning move, not a value signal.

The $230 million is not noise. It is half the cash, returned to shareholders who believe management is wrong about the stock price. That is the trade.